Co-Diagnostics, Inc. to Participate in Yale University SalivaDirect™ Conference Held July 28-29 in Chicago

Rhea-AI Summary

Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in the Yale School of Public Health SalivaDirect™ Conference on July 28-29 in Chicago. The conference focuses on promoting saliva-based testing for infectious diseases. CEO Dwight Egan and Chairman of the Scientific Advisory Board Dr. Carl Wittwer will present on the topic "The Opportunity for A New Global Response To Infectious Disease" on July 29th at 3:00 PM CT. Co-Diagnostics specializes in molecular diagnostics, developing advanced technologies for testing infectious diseases and genetic markers.

News Market Reaction – CODX

-1.16%

-1.16% Session move

In the trading session that priced this news, CODX declined 1.16%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, July 27, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be attending and speaking at the Yale School of Public Health SalivaDirect™ Conference held July 28-29 in Chicago, Il.

The mission of Yale's SalivaDirect is to advance the use of saliva-based testing as a readily-deployable, sensitive, patient-friendly option that increases access to affordable and equitable infectious disease testing. Dwight Egan, Co-Dx CEO, and Dr. Carl Wittwer, Chairman of the Company's Scientific Advisory Board, will be presenting a talk at the conference titled "The Opportunity for A New Global Response To Infectious Disease" at 3:00 PM CT on July 29th.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-participate-in-yale-university-salivadirect-conference-held-july-28-29-in-chicago-301594194.html

SOURCE Co-Diagnostics

FAQ

What is the purpose of Co-Diagnostics' participation in the Yale SalivaDirect™ Conference?

Co-Diagnostics aims to advance the use of saliva-based testing for infectious diseases.

When is the Yale SalivaDirect™ Conference being held?

The conference is scheduled for July 28-29, 2022.

Who will represent Co-Diagnostics at the SalivaDirect™ Conference?

CEO Dwight Egan and Dr. Carl Wittwer will represent Co-Diagnostics.

What topic will be discussed by Co-Diagnostics at the conference?

They will discuss "The Opportunity for A New Global Response To Infectious Disease."

What is the significance of saliva-based testing according to the conference?

Saliva-based testing increases access to affordable and equitable infectious disease testing.